Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194245 · ClinicalTrials.gov registry record · Phase 2
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01194245 is a Phase 2 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 135 participants.
The verdict
NCT01194245, a Phase 2 study, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in basal-bolus therapy.
Interventions
- DRUG Insulin aspart
- DRUG Insulin glargine
- DRUG Insulin lispro
- DRUG Insulin glulisine
- DRUG recombinant human hyaluronidase PH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194245
The ClinicalTrials.gov registry entry for NCT01194245 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Insulin aspart is the first listed.
NCT01194245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194245 about?
NCT01194245 is a clinical study titled "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus". The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in basal-bolus therapy.
What is the current status of trial NCT01194245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2010-08. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01194245?
The interventions under investigation include: Insulin aspart (DRUG), Insulin glargine (DRUG), Insulin lispro (DRUG), Insulin glulisine (DRUG), recombinant human hyaluronidase PH20 (DRUG).
Who is sponsoring clinical trial NCT01194245?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.